Company intelligence / Profile preview
Araclon Biotech
Zaragoza, Zaragoza, Spainaraclon.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Araclon Biotech has completed recruitment for Phase II clinical trials of its Alzheimer's vaccine ABvac40, with positive data from the first part of the trial showing potential to slow disease progression. The vaccine induces a strong immune response characterized by increased anti-Aβ40 titers while Aβ40 levels rise in plasma. The company has also obtained CE mark for its early-stage Alzheimer's disease diagnostic tests.[8][10]
- Therapeutic areas
- Neurology
- Modalities
- Vaccines (active immunotherapy)diagnostic tests
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Grifols
Beyond the preview
Go deeper on Araclon Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Araclon Biotech.